Anna Kotulska

Publications of Anna Kotulska

• Serum ghrelin in female patients with rheumatoid arthritis during treatment with infliximab.

  Authors: Michal Magiera, Magdalena Kopec-Medrek, Małgorzata Widuchowska, Anna Kotulska, Tomasz Dziewit, Damian Ziaja, Eugene J Kucharz, Beata Logiewa-Bazger, Wlodzimierz Mazur

  Rheumatology international. 12/2011;

  Ghrelin is a gastric hormone that posses multiple functions, including induction of growth hormone release, regulation of proinflammatory cytokines and control of food intake and energy homeostasis.Ghrelin is a gastric hormone that posses multiple functions, including induction of growth hormone release, regulation of proinflammatory cytokines and control of food intake and energy homeostasis. A few reports on serum ghrelin level in chronic inflammatory states revealed contradictory results. The study was undertaken to determine ghrelin in patients with rheumatoid arthritis receiving infliximab, a TNF-α blocking agent. Serum ghrelin was determined in 18 female rheumatoid patients before the treatment with infliximab, 1 week after the first infusion and after 53 weeks of medication and compared with 15 age-matched healthy women. Serum ghrelin level was shown to be increased in the patients. A decrease in serum ghrelin level was found after the first infusion of infliximab and similarly decreased ghrelin level but still higher than in the control was shown in the 53rd week of medication. The obtained results suggest that ghrelin level is related to inflammation, and its serum level in patients with severe rheumatoid arthritis behaves similarly to acute-phase reactants.

• Plasma leptin and neuropeptide Y concentrations in patients with rheumatoid arthritis treated with infliximab, a TNF-α antagonist.

  Authors: Magdalena Kopec-Medrek, Anna Kotulska, Malgorzata Widuchowska, Marcin Adamczak, Andrzej Więcek, Eugene J Kucharz

  Rheumatology international. 11/2011;

  TNF-α is one of the key proinflammatory cytokines in pathogenesis of rheumatoid arthritis (RA). TNF-α was also found to enhance synthesis of leptin. Leptin is mainly adipocyte-derived hormoneTNF-α is one of the key proinflammatory cytokines in pathogenesis of rheumatoid arthritis (RA). TNF-α was also found to enhance synthesis of leptin. Leptin is mainly adipocyte-derived hormone controlling appetite and energy expenditure. It acts through inhibition of neuropeptide Y secretion. It is possible that TNF-α-induced leptin secretion contributes to body mass reduction in patients with RA. The study was designed to determine the influence of inactivation of the TNF-α with infliximab on plasma leptin and neuropeptide Y concentrations in patients with RA. Sixteen female patients with RA treated with infliximab and 16 healthy women were investigated. Plasma leptin and neuropeptide Y concentrations were determined before, during and after 1 year management of the patients with infliximab and were compared with body mass index and body fatty and lean mass. There was no difference in plasma leptin concentration between the rheumatoid patients before therapy and the controls (15.6 ± 1.85 and 14.5 ± 2.15 ng/ml, respectively). Neuropeptide Y concentration was higher in the patients than in the controls (54.5 ± 3.96 and 24.8 ± 2.80 pmol/l, respectively). Treatment with infliximab resulted in enhancement in leptin concentration (18.5 ± 2.34 ng/ml) and a slight increase in neuropeptide Y concentration (58.7 ± 4.66 pmol/l). Physiological relationship between leptin and body mass was shown in the patients and was not altered during the treatment. There was no significant correlation between the disease activity and plasma leptin or neuropeptide Y concentrations.

• Serum human cartilage glycoprotein-39 in patients with systemic sclerosis: relationship to skin and articular manifestation.

  Authors: Dominika Wcislo-Dziadecka, Anna Kotulska, Ligia Brzezińska-Wcislo, Malgorzata Widuchowska, Anna Lis-Swiety, Magdalena Kopec-Medrek, Eugene J Kucharz

  Clinical rheumatology. 08/2010; 29(8):933-5.

  Human cartilage glycoprotein-39 (HC gp-30) is a secretory protein of several types of cells including chondrocytes. It has been suggested to be a laboratory index of joint damage. Thirty-two patientsHuman cartilage glycoprotein-39 (HC gp-30) is a secretory protein of several types of cells including chondrocytes. It has been suggested to be a laboratory index of joint damage. Thirty-two patients with systemic sclerosis (SSc) and 22 age-matched controls were investigated. An increased serum HC gp-39 level was shown in SSc patients and was found to correlate with inflammatory indices. There was no correlation with modified Rodnan score, joint involvement, or duration of symptoms of SSc. The obtained results indicate for possible relationship of HCgp-39 to inflammation but do not suggest determination of HC gp-39 as clinically applicable index of articular involvement in SSc patients.

• Carpal tunnel syndrome as the early symptom of rapidly progressive systemic sclerosis in men.

  Authors: Małgorzata Widuchowska, Anna Kotulska, Magdalena Kopeć-Medrek, Eugeniusz Józef Kucharz

  Wiadomości lekarskie (Warsaw, Poland : 1960). 01/2010; 63(1):33.

• Exacerbated course of atrophoderma of Pasini and Pierini in patient with papillary cancer of the thyroid gland.

  Authors: Magdalena Kopeć-Medrek, Anna Kotulska, Elzbieta Zycińska-Debska, Małgorzata Widuchowska, Eugeniusz Józef Kucharz

  Wiadomości lekarskie (Warsaw, Poland : 1960). 01/2010; 63(1):24-6.

  Atrophoderma of Pasini and Pierini is a benign cutaneous atrophy skin to morphea en plaques on repression and is considered as systemic sclerosis-like disorder. A case of female patient withAtrophoderma of Pasini and Pierini is a benign cutaneous atrophy skin to morphea en plaques on repression and is considered as systemic sclerosis-like disorder. A case of female patient with atrophoderma of Pasini and Pierini in whom rapid eruption of new plaques was found after many years of stable disease in described. Papillary cancer of the thyroid gland was diagnosed and acceleration of atrophoderma should be considered as paraneoplastic syndrome.

• Serum human cartilage glycoprotein-39 levels in patients with systemic lupus erythematosus.

  Authors: Dominika Wcisło-Dziadecka, Anna Kotulska, Ligia Brzezińska-Wcisło, Eugeniusz J Kucharz, Anna Lis-Swiety, Grazyna Kamińska-Wiciorek

  Polskie archiwum medycyny wewnȩtrznej. 12/2009; 119(12):777-84.

  INTRODUCTION: Human cartilage glycoprotein-39 (HC gp-39) is a protein secreted by various cells including chondrocytes. Serum HC gp-39 has been suggested to be a marker of cartilage damage. However,INTRODUCTION: Human cartilage glycoprotein-39 (HC gp-39) is a protein secreted by various cells including chondrocytes. Serum HC gp-39 has been suggested to be a marker of cartilage damage. However, inflammation involving other sites than the joints is an additional factor that increases the serum level of HC gp-39. OBJECTIVES: The aim of the study was to evaluate the usefulness of HC gp-39 determination in serum of patients with systemic lupus erythematosus (SLE) as a marker of joint involvement. PATIENTS AND METHODS: Serum HC gp-39 levels were measured in 25 patients with SLE and 22 healthy controls. SLE activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index, and articular involvement by calculating the number of swollen and tender joints. The markers of inflammation (erythrocyte sedimentation rate, C-reactive protein) were determined. RESULTS: We observed an increase in HC gp-39 in SLE patients. However, there was no correlation of this parameter with disease activity, inflammatory markers (except serum gamma globulin levels), and articular involvement. CONCLUSIONS: The study suggests that increased HC gp-39 in SLE patients results mainly from inflammation and is not useful as a marker of joint involvement.

• Adiposis dolorosa with hypercholesterolemia and premature severe generalized atherosclerosis.

  Authors: Ilona Szypula, Anna Kotulska, Marta Szopa, Robert Pieczyrak, Eugeniusz J Kucharz

  Wiadomości lekarskie (Warsaw, Poland : 1960). 01/2009; 62(1):64-5.

• Seronegative arthritis in patient with solitary bone plasmacytoma.

  Authors: Anna Blach, Elzbieta Zycinska-Debska, Aleksandra Zon-Giebel, Michal Banas, Anna Kotulska, Eugene J Kucharz

  Clinical rheumatology. 08/2007; 26(7):1167-8.

  We report a patient with localized focus of the bone destruction due to a rare disease, solitary bone plasmacytoma (SBP). The patient suffered from arthritis, mimicking seronegative rheumatoidWe report a patient with localized focus of the bone destruction due to a rare disease, solitary bone plasmacytoma (SBP). The patient suffered from arthritis, mimicking seronegative rheumatoid arthritis. To our knowledge, it is the first description of coexistence of arthritis and SBP.

• [Pathophysiological role of endostatin in non-malignant disorders]

  Authors: Eugeniusz Józef Kucharz, Anna Kotulska

  Polskie archiwum medycyny wewnȩtrznej. 07/2006; 115(6):507-11.

• [Application of the Dietrych methodology in evaluation of the medical diagnostic therapeutic procedures]

  Authors: Eugeniusz J Kucharz, Anna Kotulska, Andrzej Zmysłowski

  Wiadomości lekarskie (Warsaw, Poland : 1960). 02/2006; 59(3-4):293-4.

• Behçet's disease in Poland.

  Authors: Anna Kotulska, Eugene J Kucharz, Magdalena Kopeć

  Clinical rheumatology. 12/2005; 24(6):667-8.

• [Fever of unknown origin]

  Authors: Katarzyna Jankiewicz-Ziobro, Maciej Lewicki, Anna Kotulska, Eugeniusz Józef Kucharz

  Polskie archiwum medycyny wewnȩtrznej. 10/2005; 114(3):913-7.

• Did the ancient Greeks have a god of internal medicine?

  Authors: Eugene J Kucharz, Anna Kotulska

  European journal of internal medicine. 09/2005; 16(4):287.

• [Musculoskeletal manifestations as the first symptom of acute lymphoblastic leukemia. A case report]

  Authors: Michał Banaś, Anna Kotulska, J Eugeniusz Kucharz, Sławomira Kyrcz-Krzemień, Jerzy Hołowiecki

  Polskie archiwum medycyny wewnȩtrznej. 08/2005; 114(1):681-3.

• [Undifferenciated vasculitis]

  Authors: Eugeniusz Józef Kucharz, Anna Kotulska

  Polskie archiwum medycyny wewnȩtrznej. 07/2005; 113(6):631-2.

• [Application of etanercept in treatment of juvenile idiopathic arthritis and adult onset still disease]

  Authors: Maciej Lewicki, Anna Kotulska, Eugeniusz Józef Kucharz

  Polskie archiwum medycyny wewnȩtrznej. 06/2005; 113(5):505-8.

• [ Ewing's sarcoma]

  Authors: Michal Banaś, Anna Kotulska, Anna Błach, Maciej Lewicki, Aleksandra Zoń-Giebel, Magdalena Olszanecka-Glinianowicz, Eugeniusz J Kucharz

  Polskie archiwum medycyny wewnȩtrznej. 12/2004; 112(5):1351-5.

• [Schnitzler's syndrome]

  Authors: Maciej Lewicki, Katarzyna Lewicka, Przemysław Jacek Kotyla, Anna Kotulska, Joanna Goździk, Anna Błach, Michał Banaś, Eugeniusz Józef Kucharz

  Polskie archiwum medycyny wewnȩtrznej. 07/2004; 111(6):735-41.

• Pulmonary functional abnormalities in asymptomatic patients with systemic sclerosis.

  Authors: Czeslaw Marcisz, Eugene Kucharz, Ligia Brzezińska-Wcislo, Anna Kotulska, Gerard Jonderko

  European journal of internal medicine. 06/2003; 14(3):162-165.

  BACKGROUND: Systemic sclerosis (SSc) is a disease characterized by widespread fibrosis of the skin and multiple organs, including the lungs. This study was designed to evaluate pulmonary function inBACKGROUND: Systemic sclerosis (SSc) is a disease characterized by widespread fibrosis of the skin and multiple organs, including the lungs. This study was designed to evaluate pulmonary function in SSc patients without symptoms of lung involvement. METHODS: Spirometric measurements were done in 26 female SSC patients without symptoms of pulmonary involvement. RESULTS: Maximal voluntary ventilation was found to be decreased in half of the patients, and forced vital capacity was decreased in 23% of the patients. Forced expiratory flow rate was impaired in about half of the SSc patients, especially the flow at 50-75% of forced vital capacity. Peak expiratory flow rate was decreased in 77% of asymptomatic patients. CONCLUSIONS: A functional defect, mainly of the restrictive type, was observed in the majority of asymptomatic patients with SSc. Pulmonary function testing is recommended for all SSc patients.

• [Cogan's syndrome]

  Authors: Anna Kotulska, Robert Pieczyrak, Barbara Stawiarska-Pieta, Eugeniusz Józef Kucharz

  Polskie archiwum medycyny wewnȩtrznej. 04/2003; 109(3):293-7.